Ken Pastor
Fundador en CTI Life Sciences Fund .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Jean-Francois Leprince | M | - |
CTI Capital, Inc.
CTI Capital, Inc. Investment ManagersFinance CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal.
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
Pierre LaPalme | M | 83 |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | 12 años |
Michael Seckler | M | 59 |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
Thomas Schuetz | M | 63 |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
Gaétan Gravel | M | - |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
Shermaine Tilley | M | 72 |
CTI Capital, Inc.
CTI Capital, Inc. Investment ManagersFinance CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal. | - |
Laurence Rulleau | M | - |
CTI Capital, Inc.
CTI Capital, Inc. Investment ManagersFinance CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal. | 10 años |
Anjan Aralihalli | M | - |
CTI Capital, Inc.
CTI Capital, Inc. Investment ManagersFinance CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal. | 7 años |
Youssef Bennani | M | 63 |
CTI Life Sciences Fund
CTI Life Sciences Fund Miscellaneous Commercial ServicesCommercial Services CTI Life Sciences Fund provides life science related services. The private company is based in Montréal, Canada. The Canadian company was founded in 2006 by Kenneth Pastor. | 3 años |
Aleksandr Lazaryan | M | - |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
Nicole Blijlevens | F | - |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
Xin Hang | M | - |
CTI Capital, Inc.
CTI Capital, Inc. Investment ManagersFinance CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal. | 2 años |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Canadá | 12 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Ken Pastor
- Red Personal